quinazolines has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 47 (92.16) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZS; Li, D; Qiu, Y; Wu, L; Xu, J; Xu, S; Yang, DH; Yao, H; Zhou, M | 1 |
| Rosengren, RJ; Taurin, S | 1 |
| Armeson, K; Britten, C; Erlander, M; Ethier, S; Giordano, A; Kappler, C; Liu, Y; Park, Y; Reuben, J; Ridinger, M; Yeh, E | 1 |
| Huang, JJ; Jiang, WQ; Kipps, TJ; Lin, X; Wu, L; Zhang, J; Zhang, S | 1 |
| Hou, H; Kang, J; Li, D; Li, J; Li, X; Tian, W; Zhai, L; Zhong, Y | 1 |
| He, K; Liu, C; Liu, Z; Ma, Q; Ndege, I; Wang, X; Yu, Q; Yu, Z | 1 |
| Al-Ejeh, F; Dong, L; Fairlie, DP; Harris, JM; Khanna, KK; Liu, L; Ward, A; Wiegmans, AP | 1 |
| Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR | 1 |
| Baxter, RC; Boyle, FM; de Silva, HC; Julovi, SM; Lin, MZ; Martin, JL | 1 |
| He, W; Huang, S; Ji, D; Lan, H; Li, L; Li, Z; Liu, X; Wang, Y; Wu, Z; Xu, J; Yang, F; Zhang, W; Zhou, W | 1 |
| Jafari, M; Kim, J; Lee, JY; Ruiz-Torres, SJ; Sriram, V; Waltz, SE; Zhou, Z | 1 |
| Asselah, J; Badescu, D; Basik, M; Bertos, NR; Blanchet-Cohen, A; Guiot, MC; Kleinman, CL; Liu, L; Meterissian, S; Munoz-Ramos, V; Omeroglu, A; Park, M; Petrecca, K; Ragoussis, J; Revil, T; Saleh, SMI; Savage, P; Wang, YC; Zuo, D | 1 |
| Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU | 1 |
| Hu, JX; Liu, LM; Liu, XR; Wan, HP; Zhang, XQ; Zhou, LH | 1 |
| Kwak, SJ; Seong, YS; Yi, YW; You, KS | 1 |
| Brown, KK; Chan, H; Chheang, C; Daly, RJ; Huang, C; Lee, RS; Li, F; Ma, X; Mitchell, CA; Nguyen, E; Rodgers, SJ; Schittenhelm, RB; Simpson, KJ; Song, J; Wu, J; Zhang, L | 1 |
| Abedini, S; Pasdar, A; Rivandi, M; Sahebkar, A; Tajbakhsh, A | 1 |
| Annunziata, CM; Cao, L; Cimino-Mathews, A; Figg, WD; Gatti-Mays, M; Houston, ND; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Mikkilineni, L; Nichols, E; Peer, C; Sharma, R; Trepel, JB; Zimmer, AS | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Baxter, RC; de Silva, HC; Lin, MZ; Martin, JL; Scott, CD | 1 |
| Ali, SM; Alpaugh, RK; Buell, JK; Cristofanilli, M; Downing, SR; Lipson, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Wu, H; Yu, JQ | 1 |
| Choi, JS; Choi, YL; Jung, K; Kim, YJ; Kundu, J; Kwon, MJ; Lee, SE; Oh, E; Seo, J; Shin, YK; Song, JY | 1 |
| Chen, CH; Chen, WS; Chen, YJ; Hsia, TC; Hsu, KW; Hsu, MH; Huang, WC; Liu, LC; Tu, CY; Wei, YL; Yeh, MH; Yu, MC | 1 |
| Arima, Y; Hosonaga, M; Kohno, N; Saya, H; Sugihara, E | 1 |
| Baumann, C; Gusenbauer, S; Kéri, G; Őrfi, L; Pénzes, K; Szabadkai, I; Torka, R; Ullrich, A | 1 |
| Beck, D; Brandl, MB; Kavallaris, M; Li, F; Pasquier, E; Wong, ST; Zhang, S; Zhao, H | 1 |
| Bose, S; Chen, J; Cui, X; Cui, Y; Giuliano, AE; Han, B; Jin, Y; Karlan, BY; Orsulic, S; Wiedemeyer, R; Zhang, X | 1 |
| Boerner, JL; Bollig-Fischer, A; Madden, JM; Mattingly, RR; Mueller, KL; Stemmer, P | 1 |
| Han, J; Jeon, M; Jung, T; Kil, WH; Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ | 1 |
| Liu, Q; Liu, Z; Song, H; Wang, L; Wang, X; Yu, Q; Yu, Z | 1 |
| Bellizzi, A; Cardone, RA; Forciniti, S; Greco, MR; Paradiso, A; Reshkin, SJ; Rubino, R; Zeeberg, K | 1 |
| Chen, Y; Deng, M; Liu, D; Wang, J; Zhang, L | 1 |
| Jing, T; Pang, X; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zheng, X | 1 |
| Piccart, M; Sonnenblick, A | 1 |
| Heravi, M; Jean-Claude, BJ; Kumala, S; Muanza, TM; Rachid, Z; Radzioch, D | 1 |
| Bae, EJ; Bae, I; Kwak, SJ; Seong, YS; Yi, YW; You, K | 1 |
| Bevilacqua, S; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Normanno, N | 1 |
| Ethier, SP; Soloff, AC; Williams, CB; Yeh, ES | 1 |
| Chen, YJ; Hsiao, YC; Huang, WC; Liu, JF; Tang, CH; Yeh, MH | 1 |
| Chen, KF; Chen, MH; Chen, YT; Chu, PY; Hsu, CC; Hsu, CJ; Hu, MH; Huang, CT; Lee, CH; Liu, CY; Shiau, CW; Tsai, WC; Tseng, LM; Wang, DS | 1 |
| Jiang, T; Jiang, X; Pang, X; Pang, Z; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zhao, J; Zheng, X | 1 |
| Denkert, C; Diebold, K; Eidtmann, H; Fasching, PA; Glados, M; Habeck, JO; Heck, E; Holms, F; Ingold Heppner, B; Krabisch, P; Lederer, B; Loibl, S; Lorenz, P; Ober, A; Pfitzner, BM; Rezai, M; Schmitt, W; Solbach, C; Tesch, H; Untch, M; Zahm, DM | 1 |
| He, KW; Huo, ZJ; Liu, ZY; Ma, QH; Song, XG; Wang, XW; Wang, XZ; Yu, ZY; Zhuo, PY | 1 |
| Al-Daccak, R; Antonicelli, F; Bastid, J; Bensussan, A; Cure, H; Fabre, J; Fuselier, C; Garbar, C; Giustiniani, J; Merrouche, Y | 1 |
| Gonçalves, A | 1 |
| Blohmer, JU; Darb-Esfahani, S; Denkert, C; Dietel, M; Endris, V; Jackisch, C; Klare, P; Kümmel, S; Loi, S; Loibl, S; Möbs, M; Nekljudova, V; Reimer, T; Salat, C; Schem, C; Schmitt, W; Sinn, B; Sinn, P; Stenzinger, A; Tesch, H; Untch, M; von Minckwitz, G; Weichert, W | 1 |
| Holtrich, U; Karn, T; Kedan, A; Kothari, C; Lev, S; Mills, GB; Müller, AK; Nguyen, LK; Panayotopoulou, E; Selitrennik, M; Shin, S; Verma, N | 1 |
| Emons, G; Girgert, R; Gründker, C | 1 |
| Fulton, AM; Kochel, TJ; Kundu, N; Ma, X; Reader, JC | 1 |
| Hu, XC; Lin, C; Liu, MM; Tao, ZH; Wu, ZH; Zhang, J | 1 |
| Boerner, JL; Kuperwasser, C; List, K; Madden, JM; Mueller, KL; Zoratti, GL | 1 |
4 review(s) available for quinazolines and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review.
Topics: Anoikis; Berberine; Chlorobenzoates; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrans; Pyrroles; Quinazolines; Saponins; Signal Transduction; Styrenes; Triple Negative Breast Neoplasms | 2019 |
Adjuvant systemic therapy in breast cancer: quo vadis?
Topics: Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Mastectomy; Paclitaxel; Patient Selection; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Tamoxifen; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triple Negative Breast Neoplasms | 2015 |
[Not Available].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Neoadjuvant Therapy; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2016 |
2 trial(s) available for quinazolines and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Topics: Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Lapatinib; Lymphocytes; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2016 |
45 other study(ies) available for quinazolines and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Heterocyclic Compounds; Humans; Polycyclic Compounds; Quinazolines; Triple Negative Breast Neoplasms | 2021 |
Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Raloxifene Hydrochloride; Triple Negative Breast Neoplasms | 2022 |
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Thiophenes; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Aurora B induces epithelial-mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis.
Topics: Animals; Aurora Kinase B; Breast Neoplasms; Carcinoma, Ductal; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Neoplasm Invasiveness; Neoplasm Metastasis; Octamer Transcription Factor-3; Organophosphates; Phosphorylation; Protein Kinase Inhibitors; Protein Stability; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Triple Negative Breast Neoplasms | 2020 |
A novel anthraquinone‑quinazoline hybrid 7B blocks breast cancer metastasis and EMT via targeting EGFR and Rac1.
Topics: Anthraquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Models, Molecular; Molecular Docking Simulation; Neoplasm Metastasis; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms | 2021 |
Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer.
Topics: Adenine; Animals; Autophagy; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Macrolides; Mice; Mice, Nude; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cinnamates; DNA Damage; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Quinazolines; Quinazolinones; Rad51 Recombinase; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2017 |
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Topics: Animals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Fingolimod Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Insulin-Like Growth Factor Binding Protein 3; Mice; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance.
Topics: Adult; Aniline Compounds; Antineoplastic Agents, Phytogenic; bcl-X Protein; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin G1; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Polyploidy; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; Sulfonamides; Triple Negative Breast Neoplasms | 2017 |
Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Doxorubicin; ErbB Receptors; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Lactates; Mice; Nanocapsules; Polyethylene Glycols; Quinazolines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
Topics: Animals; BRCA1 Protein; ErbB Receptors; Female; Gefitinib; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Fluorescence; Protein Kinase Inhibitors; Quinazolines; RNA, Neoplasm; Sequence Analysis, RNA; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2017 |
UNC0638, a G9a inhibitor, suppresses epithelial‑mesenchymal transition‑mediated cellular migration and invasion in triple negative breast cancer.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Neoplastic Stem Cells; Quinazolines; Triple Negative Breast Neoplasms | 2018 |
Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Regulatory-Associated Protein of mTOR; Ribosomal Protein S6; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2018 |
Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Immediate-Early Proteins; Mass Spectrometry; Mice, Inbred BALB C; Mice, Nude; Oncogenes; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2014 |
MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Middle Aged; Molecular Targeted Therapy; Neoplasms, Basal Cell; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfones; Triple Negative Breast Neoplasms | 2014 |
Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Hydroxamic Acids; Lapatinib; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Triple Negative Breast Neoplasms | 2014 |
Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Topics: Animals; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cell Line; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Lapatinib; Ligands; Mice; Myelin Proteins; Neoplasms; Nogo Receptor 1; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Cell Surface; Transcription, Genetic; Transcriptional Activation; Triple Negative Breast Neoplasms | 2014 |
Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Drug Synergism; Female; Humans; Kinesins; Mice; Mice, Inbred BALB C; Mitosis; Pyrimidines; Quinazolines; Thiones; Triple Negative Breast Neoplasms; Vinblastine; Xenograft Model Antitumor Assays | 2014 |
FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transfection; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Eukaryotic Initiation Factors; Female; Gefitinib; HEK293 Cells; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2014 |
Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Female; Fibronectins; Gefitinib; Humans; MCF-7 Cells; Phosphorylation; Quinazolines; Signal Transduction; Silybin; Silymarin; Triple Negative Breast Neoplasms; Tyrphostins | 2014 |
Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Mice; Phosphatidylinositol 3-Kinase; Quinazolines; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
Topics: Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Invasiveness; Phosphoproteins; Plakins; Protein Transport; Pseudopodia; Quinazolines; Sodium-Hydrogen Exchangers; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2015 |
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Chromones; Drug Interactions; ErbB Receptors; Female; Gefitinib; Humans; Oligopeptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2015 |
The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Female; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Quinazolines; Serum Albumin; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
ZRBA1, a Mixed EGFR/DNA Targeting Molecule, Potentiates Radiation Response Through Delayed DNA Damage Repair Process in a Triple Negative Breast Cancer Model.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Damage; DNA Repair; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance; Time Factors; Triazenes; Triple Negative Breast Neoplasms; Tumor Stem Cell Assay | 2015 |
Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Indoles; Peptide Library; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Ribosomal Protein S6; Sulfonamides; Triple Negative Breast Neoplasms | 2015 |
EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Topics: Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Triple Negative Breast Neoplasms | 2015 |
Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
Topics: Antineoplastic Agents; Blotting, Western; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Immunoprecipitation; Interleukin-6; Lapatinib; MicroRNAs; Mitogen-Activated Protein Kinase 1; Phosphorylation; Proto-Oncogene Proteins c-raf; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2015 |
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autoantigens; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; MCF-7 Cells; Membrane Proteins; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Drug Carriers; Drug Compounding; Drug Stability; Female; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Phosphatidylcholines; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Tissue Distribution; Triple Negative Breast Neoplasms | 2016 |
[Effect of autophagy inhibitor combined with EGFR inhibitor on triple-negative breast cancer MDA-MB-468 and MDA-MB-231 cells].
Topics: Adenine; Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Macrolides; MCF-7 Cells; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Triple Negative Breast Neoplasms | 2016 |
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Topics: Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-17; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2016 |
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Female; Fluorescent Antibody Technique; Focal Adhesion Kinase 2; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Mice; Nedd4 Ubiquitin Protein Ligases; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2017 |
17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Topics: Antineoplastic Agents; Aromatase; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin D1; ErbB Receptors; Estradiol; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Phosphorylation; Quinazolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; src-Family Kinases; Triple Negative Breast Neoplasms | 2017 |
Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Movement; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxyprostaglandin Dehydrogenases; MCF-7 Cells; Mice, Inbred BALB C; Mice, SCID; Multidrug Resistance-Associated Proteins; Neoplasm Metastasis; Organic Anion Transporters; Propionates; Quinazolines; Quinolines; Receptors, Prostaglandin E, EP4 Subtype; RNA Interference; Signal Transduction; Time Factors; Transfection; Triple Negative Breast Neoplasms; Tumor Microenvironment; Tyrphostins | 2017 |
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzodioxoles; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Focal Adhesion Kinase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 3; Octamer Transcription Factor-3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Survivin; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2016 |
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Coculture Techniques; Culture Media, Conditioned; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Gefitinib; Gene Expression; Hepatocyte Growth Factor; Humans; Paracrine Communication; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Triple Negative Breast Neoplasms | 2012 |